Therefore, our study suggests the potential value of AIL as a targeted inhibitor of c-Jun, either in isolation, or to enhance the effectiveness of the current PD-L1 checkpoint blockade immunotherapy in melanoma (Fig. 7). The gene discussed is JUN; the disease is melanoma.